{"id":"14c-ly404039","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T06:31:43.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123339,"model":"claude-sonnet-4-5-20250929"},"description":"14C-LY404039 is a radiolabeled version of LY404039, a compound developed by Denovo Biopharma LLC currently in Phase 1 clinical development. The radiolabeled form is used in pharmacokinetic and metabolism studies to track drug distribution and elimination in the body.","indications":{"approved":[{"status":"investigational","condition":"Pharmacokinetic study","patientPopulation":"Adult healthy volunteers or patients"}]},"trialDetails":[{"nctId":"NCT01637142","phase":"PHASE1","title":"A Study of LY2140023 in Healthy Participants","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2012-07","conditions":"Healthy Participants","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"14C-LY404039","genericName":"14C-LY404039","companyName":"Denovo Biopharma LLC","companyId":"denovo-biopharma-llc","firstApprovalDate":"","aiSummary":"14C-LY404039 is a small molecule that acts as a metabotropic glutamate receptor 2 agonist. It was studied in a clinical trial (NCT01637142) as part of an absolute bioavailability study in healthy participants.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}